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ABSTRACT
The British Society of Gastroenterology in collaboration 
with British Association for the Study of the Liver has 
prepared this document. The aim of this guideline is to 
review and summarise the evidence that guides clinical 
diagnosis and management of ascites in patients with 
cirrhosis. Substantial advances have been made in 
this area since the publication of the last guideline in 
2007. These guidelines are based on a comprehensive 
literature search and comprise systematic reviews in the 
key areas, including the diagnostic tests, diuretic use, 
therapeutic paracentesis, use of albumin, transjugular 
intrahepatic portosystemic stent shunt, spontaneous 
bacterial peritonitis and beta- blockers in patients with 
ascites. Where recent systematic reviews and meta- 
analysis are available, these have been updated with 
additional studies. In addition, the results of prospective 
and retrospective studies, evidence obtained from expert 
committee reports and, in some instances, reports 
from case series have been included. Where possible, 
judgement has been made on the quality of information 
used to generate the guidelines and the specific 
recommendations have been made according to the 
’Grading of Recommendations Assessment, Development 
and Evaluation (GRADE)’ system. These guidelines are 
intended to inform practising clinicians, and it is expected 
that these guidelines will be revised in 3 years’ time.
EXECUTIVE SUMMARY OF RECOMMENDATIONS
1. Diagnostic paracentesis in new- onset ascites
1.1. A diagnostic paracentesis is recommended 
in all patients with new- onset ascites. (Qual-
ity of evidence: moderate; Recommendation: 
strong)
1.2. The initial ascitic fluid analysis should in-
clude total protein concentration and calcu-
lation of the serum ascites albumin gradient 
(SAAG). (Quality of evidence: moderate; Rec-
ommendation: strong)
1.3. Ascites fluid analysis for cytology, amylase, 
brain natriuretic peptide (BNP) and adenosine 
deaminase should be considered based on pre-
test probability of specific diagnosis (Quality of 
evidence: moderate; Recommendation: weak)
2. Spontaneous bacterial peritonitis
2.1. Diagnostic paracentesis should be carried 
out without a delay to rule out spontaneous 
bacterial peritonitis SBP) in all cirrhotic patients 
with ascites on hospital admission. (Quality of 
evidence: moderate; Recommendation: strong)
2.2. A diagnostic paracentesis should be per-
formed in patients with GI bleeding, shock, 
fever or other signs of systemic inflammation, 
gastrointestinal symptoms, hepatic encephalop-
athy, and in patients with worsening liver or 
renal function. (Quality of evidence: moderate; 
Recommendation: strong)
2.3. Ascitic neutrophil >250/mm3 count re-
mains the gold standard for the diagnosis of SBP 
and this can be performed either by manual mi-
croscopy or using automated counts, based on 
flow cytometry for counting and differentiating 
cells. (Quality of evidence: moderate; Recom-
mendation: strong)
2.4. Ascitic fluid culture with bedside inoc-
ulation of blood culture bottles should be 
performed to guide the choice of antibiotic 
treatment when SBP is suspected. (Quality of 
evidence: moderate; Recommendation: strong)
2.5. Immediate empirical antibiotic therapy 
should be determined with due consideration of 
context of SBP (community acquired or health-
care associated), severity of infection and lo-
cal bacterial resistance profile. Cefotaxime has 
been widely studied, but choice of antibiotic 
should be guided by local resistance patterns 
and protocol. (Quality of evidence: moderate; 
Recommendation: strong)
2.6. A second diagnostic paracentesis at 48 
hours from the start of treatment to check the 
efficacy of antibiotic therapy should be consid-
ered in those who have apparently inadequate 
response or where secondary bacterial peritoni-
tis is suspected. (Quality of evidence: low; Rec-
ommendation: weak)
2.7. Patients presenting with gastrointestinal 
bleeding and underlying ascites due to cirrhosis 
should receive prophylactic antibiotic treatment 
(cefotaxime has been widely studied but the an-
tibiotic should be chosen based on local data) 
to prevent the development of SBP. (Quality of 
evidence: strong; Recommendation: strong)
2.8. Patients who have recovered from an ep-
isode of SBP should be considered for treat-
ment with norfloxacin (400 mg once daily), 
ciprofloxacin (500 mg once daily, orally) or co- 
trimoxazole (800 mg sulfamethoxazole and 160 
mg trimethoprim daily, orally) to prevent fur-
ther episode of SBP. (Quality of evidence: low; 
Recommendation: weak)
2.9. Primary prophylaxis should be offered to 
patients considered at high risk, as defined by 
an ascitic protein count <1.5 g/dL. However, it 
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is important that the potential risks and benefits and existing 
uncertainties are communicated to patients. (Quality of evi-
dence: low; Recommendation: weak)
3. Dietary salt restriction
3.1. Patients with cirrhosis and ascites should have a mod-
erately salt restricted diet with daily salt intake of no more 
than 5–6.5 g (87–113 mmol sodium). This translates to a no 
added salt diet with avoidance of precooked meals. (Quality 
of evidence: moderate; Recommendation: strong)
3.2. Patients with cirrhosis and ascites should receive nutri-
tional counselling on the sodium content in the diet. (Quality 
of evidence: weak; Recommendation: strong)
4. Diuretics
4.1. In patients with the first presentation of moderate as-
cites, spironolactone monotherapy (starting dose 100 mg, 
increased to 400 mg) is reasonable. In those with recurrent 
severe ascites, and if faster diuresis is needed (for example, 
if the patient is hospitalised), combination therapy with 
spironolactone (starting dose 100 mg, increased to 400 mg) 
and furosemide (starting dose 40 mg, increased to 160 mg) is 
recommended. (Quality of evidence: moderate; Recommen-
dation: strong)
4.2. All patients initiating diuretics should be monitored for 
adverse events. Almost half of those with adverse events re-
quire diuretic discontinuation or dose reduction. (Quality of 
evidence: low; Recommendation: weak)
4.3. Hypovolaemic hyponatraemia during diuretic therapy 
should be managed by discontinuation of diuretics and ex-
pansion of plasma volume with normal saline. (Quality of 
evidence: low; Recommendation: weak)
4.4. Fluid restriction to 1–1.5 L/day should be reserved for 
those who are clinically hypervolaemic with severe hypon-
atraemia (serum sodium <125 mmol/L). (Quality of evi-
dence: low; Recommendation: weak)
4.5. Hypertonic sodium chloride (3%) administration should 
be reserved for those who are severely symptomatic with 
acute hyponatraemia. Serum sodium should be slowly cor-
rected. (Quality of evidence: low; Recommendation: weak)
4.6. It may be appropriate to consider use of midodrine in re-
fractory ascites on a case by case basis. (Quality of evidence: 
low; Recommendation: weak)
5. Large volume paracentesis (LVP)
5.1. Patients should give informed consent for a therapeutic 
or diagnostic paracentesis. (Quality of evidence: low; Recom-
mendation: strong)
5.2. Ultrasound guidance should be considered when availa-
ble during LVP to reduce the risk of adverse events (Quality 
of evidence: low; Recommendation: weak)
5.3. Routine measurement of the prothrombin time and 
platelet count before therapeutic or diagnostic paracente-
sis and infusion of blood products are not recommended. 
(Quality of evidence: moderate ; Recommendation: strong)
6. Use of human albumin solution (HAS)
6.1. Albumin (as 20% or 25% solution) should be infused 
after paracentesis of >5 L is completed at a dose of 8 g albu-
min/L of ascites removed. (Quality of evidence: high; Recom-
mendation: strong)
6.2. Albumin (as 20% or 25% solution) can be considered 
after paracentesis of <5 L at a dose of 8 g albumin/L of as-
cites removed in patients with ACLF or high risk of post- 
paracentesis acute kidney injury. (Quality of evidence: low; 
Recommendation: weak)
6.3. In patients with SBP and an increased serum creatinine 
or a rising serum creatinine, infusion of 1.5 g albumin/kg 
within 6 hours of diagnosis, followed by 1 g/kg on day 3, is 
recommended. (Quality of evidence: low; Recommendation: 
weak)
7. Transjugular intrahepatic portosystemic shunt (TIPSS)
7.1. TIPSS should be considered in patients with refractory 
ascites. (Quality of evidence: high; Recommendation: strong)
7.2. Caution is required if considering TIPSS in patients with 
age >70 years, serum bilirubin >50 µmol/L, platelet count 
<75×109/L, model for end- stage liver disease (MELD) score 
≥18, current hepatic encephalopathy, active infection or 
hepatorenal syndrome. (Quality of evidence: moderate; Rec-
ommendation: strong)
8. Umbilical hernia
8.1. Suitability and timing of surgical repair of umbilical her-
nia should be considered in discussion with the patient and 
multidisciplinary team involving physicians, surgeons and 
anaesthetists. (Quality of evidence: low; Recommendation: 
strong)
9. Hepatic hydrothorax (HH)
9.1. TIPSS should be considered in patients with HH after 
discussion with the multidisciplinary team. (Quality of evi-
dence: low; Recommendation: strong)
9.2. In patients with HH who are not undergoing a TIPSS 
and/or a liver transplant evaluation, alternative palliative in-
terventions should be considered. (Quality of evidence: low; 
Recommendation: strong)
10. Non- selective beta- blockers (NSBB) and ascites
10.1. Refractory ascites should not be viewed as a contrain-
dication to NSBB. (Quality of evidence: moderate; Recom-
mendation: strong)
10.2. Patients with refractory ascites who are taking NSBB 
should be monitored closely, and dose reduction or discon-
tinuation may be appropriate in those who develop hypo-
tension or acute/progressive renal dysfunction. (Quality of 
evidence: moderate; Recommendation: strong)
11. Automated low- flow ascites pump
11.1. An automated low- flow ascites pump should be con-
sidered only in special circumstances with robust arrange-
ments of clinical governance, audit or research. (Quality of 
evidence: low; Recommendation: weak)
12. Palliative care
12.1. Patients with refractory ascites who are not under-
going evaluation for liver transplant should be offered a 
palliative care referral. Besides repeated LVP, alternative 
palliative interventions for refractory ascites should also be 
considered. (Quality of evidence: weak; Recommendation: 
strong)
13. Research recommendations
13.1. Randomised controlled trials (RCT) with large sample 
size should evaluate the role of antibiotics in the secondary 
prophylaxis for SBP in ascites secondary to cirrhosis.
13.2. Large RCTs should assess the role of midodrine in the 
management of ascites.
13.3. Cost- effectiveness of long- term administration of al-
bumin to patients with decompensated cirrhosis and ascites 
should be evaluated.
13.4. Role of nutritional interventions in the management of 
ascites should be evaluated.
13.5. Large RCT of long- term carvedilol versus no carvedilol 
in patients with refractory ascites without large oesophageal 
varices should be carried out.
13.6. Role of TIPSS in the management of hepatic hydro-
thorax should be compared with other therapeutic interven-
tions.
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13.7. The cost- effectiveness and the effect of automated low- 
flow ascites pumps on the quality of life of patients with re-
fractory ascites should be evaluated.
13.8. Effectiveness and safety of long- term abdominal drains 
should be assessed in RCTs for the palliative care of patients 
with cirrhosis and refractory ascites.
PATIENT SUMMARY
These guidelines have been produced on behalf of the British 
Society of Gastroenterology (BSG) in collaboration with the 
British Association for the Study of the Liver (BASL). These 
guidelines are aimed at healthcare professionals who look after 
patients with cirrhosis and ascites.
Ascites is the build- up of fluid in the belly (abdomen). This 
occurs when the liver gets irreversibly scarred, a condition 
known as cirrhosis. Ascites is the most common complication 
of cirrhosis.
All patients with a new onset of ascites should have the fluid 
tested. This involves inserting a small needle into the abdomen 
and removing about two tablespoons of ascitic fluid. The fluid 
is then analysed for protein and white cell count. Protein count 
can help differentiate whether the cause of ascites is cirrhosis or 
whether the ascites is due to other causes like heart disease or 
cancer. The white cell count indicates whether there is an infec-
tion in the ascitic fluid. If infection is present, this is treated with 
a short course of antibiotics. Infection of ascites should be ruled 
out at every hospital admission as it carries a high risk of death 
and should therefore be diagnosed and treated promptly. After 
this initial treatment, patients are given long- term antibiotics to 
prevent repeat infections.
No salt should be added at the table to food. The total amount 
of salt in food per day should not be more than the equivalent of 
one teaspoon. Patients should read labels on prepared foods to 
confirm their daily salt intake is within the limit of 5 g of salt. The 
initial treatment for patients with ascites involves taking medica-
tion, commonly known as 'water tablets' (diuretics). These drugs 
are begun at a small dose, which is gradually increased until the 
ascites is treated. Diuretics can have side effects such dehydra-
tion, confusion, abnormal levels of sodium and potassium and 
kidney damage. Therefore patients should be monitored while 
taking these tablets.
As the liver disease progresses the ascites may no longer 
respond to medication. This is known as untreatable or refrac-
tory ascites. This requires the patient to come into hospital every 
few weeks to have a temporary drain inserted into the abdomen 
and the ascitic fluid drained. If more than 5 L of fluid is removed, 
patients are also given a protein solution into the vein to prevent 
dehydration.
In patients with untreatable ascites, alternatives to repeated 
hospital drainage include placing a small tube (stent) in the liver. 
This specialised procedure is known as a transjugular intrahepatic 
portosystemic shunt (TIPSS). The TIPSS procedure is effective in 
reducing the need for repeated fluid drainage. Because of potential 
side effects, patients should be selected carefully for this proce-
dure. This is particularly true for patients with more advanced liver 
disease, where the insertion of a TIPSS can potentially be harmful.
The only curative option for untreatable ascites is liver trans-
plantation. If the patient is not suitable for liver transplantation, 
medical care then focuses on controlling the ascites symptoms. 
This is known as palliative care. The most common palliative 
treatment for untreatable ascites is repeated hospital drainage. 
Alternative treatments for untreatable ascites, such as long- term 
abdominal drains, need further research.
INTRODUCTION
Contemporary data from an NHS hospital serving a popula-
tion of 700 000, found 164 adults with a new diagnosis of 
ascites over a period of 5 years. Of these, 55% had cirrhosis 
(alcohol- related liver disease 58, non- alcoholic fatty liver 
disease 21, chronic viral hepatitis 4, autoimmune liver diseases 
3 and cryptogenic cirrhosis 4), 29% had malignancies (gynae-
cological 12, gastrointestinal 25 and others 11), 6% cardiac 
failure (CF), 3% end- stage renal disease (ESRD) and 7% other 
aetiologies.
Development of ascites is an important milestone in the natural 
history of cirrhosis. About 20% of patients with cirrhosis have 
ascites at their first presentation, and 20% of those presenting with 
ascites die in the first year of the diagnosis.1 The aim of this guide-
line is to review and summarise the evidence that guides clinical 
diagnosis and management of ascites in patients with cirrhosis.
Pathogenesis
A detailed description of the pathogenesis of ascites formation is 
beyond the scope of this article, but two key factors involved in 
the pathogenesis of ascites formation are portal hypertension and 
retention of sodium and water. This is summarised in figure 1.
An elevated sinusoidal pressure is essential for the development 
of ascites, as fluid accumulation does not develop at portal pressure 
gradient below 8 mm Hg, and rising corrected sinusoidal pressure 
correlates with decreased 24- hour urinary excretion of sodium.2 3 
Architectural changes associated with advanced fibrosis are clearly 
the primary mechanism underlying increased intrahepatic resis-
tance to the portal flow in cirrhosis. In addition, phenotypic 
changes in hepatic stellate cells and liver sinusoidal endothelial cells 
contribute to the pathophysiology. Activated stellate cells become 
contractile, and their recruitment around newly formed sinusoidal 
vessels increases the vascular resistance. Reduction in the produc-
tion/bioavailability of nitric oxide (NO) in the cirrhotic liver adds 
further to the rise in vascular tone. Overall, vasoconstriction has 
been estimated to account for about 25% of the increased resistance 
within the liver.4
Increased portal pressure is sensed by intestinal microvascula-
ture that generates angiogenic factors such as vascular endothelial 
growth factor,5 and these stimulate the development of portosys-
temic collaterals through the opening of pre- existing vessels or new 
vessel formation. When the portal pressure rises further, induction 
of endothelial nitric oxide synthase and over production of NO 
leads to splanchnic arterial vasodilatation. This, in turn, increases 
portal blood flow, thus exacerbating portal hypertension. Portosys-
temic collaterals also permit vasodilators such as NO, prostacyclin 
and endocannabinoids6 to enter the systemic circulation leading 
to a state of ‘effective hypovolaemia’.7 This activates sympathetic 
nervous system stimulating reabsorption of sodium in proximal, 
distal tubules, loop of Henle and collecting duct as well as the 
renin–angiotensin–aldosterone system, leading to sodium absorp-
tion from distal tubule and collecting duct.8 Renal sodium retention 
and eventual free water clearance due to non- osmotic release of 
arginine–vasopressin and its action on V2 receptor in the collecting 
duct underlie the fluid retention associated with oedema and ascites 
in cirrhosis.8
More recently, it has been hypothesised that bacterial trans-
location associated with portal hypertension in cirrhosis and 
related pathogen- associated, molecular pattern activated innate 
immune responses lead to systemic inflammation.9 This is asso-
ciated with vasodilatation as well as release of proinflammatory 
cytokines, reactive oxygen and nitrogen species, contributing to 
organ dysfunction.
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Definitions
The terms used in this article have been defined by the Interna-
tional Ascites Club10
Uncomplicated ascites
Ascites that is not infected and which is not associated with the 
development of the hepatorenal syndrome (HRS). Ascites can 
be graded as mild when ascites is detectable only by ultrasound 
examination, moderate when it causes moderate symmetrical 
distension of the abdomen and large when it causes marked 
abdominal distension.
Refractory ascites
Ascites that cannot be mobilised or the early recurrence of 
which (ie, after therapeutic paracentesis) cannot be satisfacto-
rily prevented by medical treatment. This includes two different 
subgroups.
Diuretic-resistant ascites
Ascites that is refractory to dietary sodium restriction and inten-
sive diuretic treatment.
Diuretic-intractable ascites
Ascites that is refractory to treatment owing to the development 
of diuretic- induced complications that preclude the use of an 
effective diuretic dosage.
Evaluation of patients with ascites
Clinical evaluation should include history of exposure to risk 
factors for cirrhosis and physical examination to look for 
evidence to support chronic liver disease or an alternative diag-
nosis. Shifting dullness is detectable when about one and a half 
litres of free fluid accumulate in the abdomen; the physical sign 
has 83% sensitivity and 56% specificity in detecting ascites.11 12 
However, in the presence of obesity or smaller amount of fluid, 
imaging such as ultrasound or CT is necessary to confirm the 
presence of ascites.
DIAGNOSTIC PARACENTESIS IN NEW-ONSET ASCITES
Aspiration of ascitic fluid and its laboratory analysis is an 
essential step in the management of patients with newly diag-
nosed ascites. In cirrhosis, hepatic sinusoids are less permeable 
owing to fibrous tissue deposition, resulting in ascites with low 
protein content. It is important to estimate total protein level 
in ascites fluid; a concentration below 1.5 g/dL (or 15 g/L) is a 
risk factor for the development of spontaneous bacterial perito-
nitis. In addition, serum ascites albumin gradient (SAAG) should 
be estimated routinely. A cut- off point of 1.1 g/dL (or 11 g/L) 
differentiates between causes of ascites with high sensitivity,13–18 
although alternative causes should be considered based on the 
clinical scenario (table 1).
Hepatic sinusoids are normally permeable in heart failure, 
which allows for leakage of protein- rich lymph into the abdom-
inal cavity and therefore, total protein concentration in ascitic 
fluid is high (>2.5 g/dL) in combination with a high SAAG. In 
such a situation, measurement of brain natriuretic peptide (BNP) 
in the serum±ascites is useful. Total protein concentrations >2.5 
g/dL within the ascites and serum BNP >364 ng/L are suggestive 
Table 1 Grouping of aetiology of ascites based on serum albumin 
ascites gradient (SAAG)
SAAG ≥11 /L SAAG <11 /L
Portal hypertension Peritoneal carcinomatosis
Cardiac failure Peritoneal tuberculosis
Portal vein thrombosis* Pancreatitis*
Hypothyroidism* Bowel perforation*
Nephrotic syndrome*
*Limited data27 283 284
Figure 1 The pathogenesis of ascites in cirrhosis.
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of underlying or additional cardiac disease, whereas serum 
protein values <182 ng/L rule out cardiac disease.19
In low SAAG states, clinical context and imaging should guide 
the investigational approach. The yield for positive cytology in 
the context of malignancy is variable, ranging from 0% to 96.7%, 
in part determined by the site of the tumour.20 21 Combining 
cytology with tumour markers in the ascitic fluid may increase 
the positive predictive value (PPV), specifically the use of carc-
inoembryonic antigen (CEA), epithelial cell adhesion molecule 
(EpCAM), CA 15-3 and CA 19-9.20 However, CA 125 in the 
serum or ascites has no role as a discriminator and will commonly 
be elevated by the presence of ascites from any cause.22
Where peritoneal TB is considered plausible, ascites can be 
sent for acid- fast bacilli smear and culture, although culture 
positivity occurs in <50% and smear- positive ascites is rare.23 
Adenosine deaminase is more useful to distinguish between peri-
toneal TB and carcinomatosis, with an area under the receiver 
operating characteristic curve of 0.98; adenosine deaminase 
levels of <40 IU/mL are used to exclude TB.24 25
Pancreatic ascites is a rare complication of pancreatitis, 
although more common when a pseudocyst is present. In 
pancreatic ascites, the amylase level in the ascitic fluid is typi-
cally >1000 IU/L or greater than six times the serum amylase, 
with mean values exceeding 4000 IU/L in a recent cohort of 80 
patients.26 Raised polymorphonuclear leucocytes (PMN) count 
may also be found in pancreatic ascites.27
The ascitic fluid samples required from the diagnostic para-
centesis is summarised in figure 2.
Recommendations
 ► A diagnostic paracentesis is recommended in all patients 
with new- onset ascites. (Quality of evidence: moderate; 
Recommendation: strong)
 ► The initial ascitic fluid analysis should include total protein 
concentration and calculation of SAAG. (Quality of evidence: 
moderate; Recommendation: strong)
 ► Ascites fluid analysis for cytology, amylase, BNP and adeno-
sine deaminase should be considered based on pretest prob-
ability of specific diagnosis (Quality of evidence: moderate; 
Recommendation: weak)
SPONTANEOUS BACTERIAL PERITONITIS (SBP)
Spontaneous bacterial peritonitis is the development of bacterial 
infection of ascites in the absence of any intra- abdominal surgically 
treatable source of infection. The prevalence of SBP in outpatients 
is 1.5–3.5% and approximately 10% in hospitalised patients.28 
A recent European study detected a prevalence of 11.3% among 
inpatients.29 When first described, mortality associated with SBP 
exceeded 90%, but, in- hospital mortality has been reduced to 
approximately 20% with early diagnosis and prompt treatment.30 
In an observational study, each hour of delay in diagnostic para-
centesis after admission was associated with a 3.3% increase of 
in- hospital mortality after adjusting for model for end- stage liver 
disease (MELD) score.31 Long- term survival remains poor; 1- year 
survival after hospitalisation with SBP in a UK study was found 
to be 34%.32 Patients recovering from an episode of SBP should 
always be considered as potential candidates for liver transplanta-
tion if they have not already been assessed.
Diagnosis of SBP
The diagnosis of SBP is confirmed when ascitic neutrophil 
count is >250 cells/mm3 in the absence of an intra- abdominal 
and surgically treatable source of sepsis. A cut- off point of 250 
neutrophils/mm3 has the greatest sensitivity, although a cut- off 
point of 500 neutrophils/mm3 has greater specificity.33 A meta- 
analysis of primary data from 14 prospective trials has defined 
the positive and negative likelihood ratios of SBP at different 
thresholds for total white cell count (WCC) and PMN in ascitic 
fluid. WCC >1000 cells/µL or PMN ≥500 cells/µL are most 
accurate and yield positive likelihood ratios of 9.1 (95% CI 5.5 
to 15.1) and 10.6 (95% CI 6.1 to 18.3), respectively. Likelihood 
ratios for WCC >500 cells/µL (5.9; 95% CI 2.3 to 15.5) and 
PMN >250 cells/µL (6.4; 95% CI 4.6 to 8.8) support routine 
clinical practice of using lower thresholds, where the greater risk 
lies with underdiagnosing SBP.18
Historically, ascitic neutrophil counts have been performed by 
manual microscopy, but, this is time and cost intensive. Automated 
counts, based on flow cytometry for counting and differentiating 
cells, are now used in most centres. This technique has been shown 
to have sensitivity and specificity close to 100%,34 35 allowing a 
tube containing ethylenediamine tetra- acetate (EDTA; as used for 
plasma full blood count) to be inoculated with ascitic fluid and 
processed on a standard blood count analyser. Reagent strips have 
insufficient sensitivity for reliable use in this context36 and hence 
cannot be recommended to replace cell count to diagnose SBP.
Ascitic fluid culture
Ascites culture is essential to help guide antibiotic therapy. 
Patients with ‘culture- negative neutrocytic ascites’ (PMN count 
>250 cells/mm3) have a similar presentation to those with 
culture- positive SBP. As both groups of patients have significant 
morbidity and mortality,37 38 they should be treated in a similar 
manner. Some patients have ‘bacterascites’ in which cultures 
are positive, but, ascitic neutrophil count is <250 cells/mm3. In 
some patients, bacterascites represents a transient and sponta-
neously reversible colonisation of ascites, in others, particularly 
those who are symptomatic, it may represent the first step in the 
development of SBP.33 Discussion with microbiologists about the 
organism cultured can help differentiate the above two scenarios, 
and when a positive culture is obtained a repeat tap should be 
sent to guide management.
Although the identification of pathogen(s) is essential for the 
management of infectious diseases, ascites fluid cultures often 
fail to provide positive results, even when using ascites samples 
Figure 2 The ascitic fluid samples required from diagnostic 
paracentesis. *These investigations should be considered based on 
pretest probability of specific diagnosis. BNP, brain natriuretic peptide.
6 Aithal GP, et al. Gut 2020;0:1–21. doi:10.1136/gutjnl-2020-321790
Guidelines
from patients who develop clinical manifestations of SBP. Bacte-
rial DNA detection and sequencing have been applied to the 
diagnosis of several infectious diseases, and molecular tech-
niques can detect small amounts of bacterial DNA within a few 
hours. These promising techniques have yet to be introduced 
into routine clinical practice.39
Fungal peritonitis is a rare, less studied complication and 
observational data suggest a worse prognosis.40 In a large multi-
centre study of 2743 cirrhotic inpatients, of whom 1052 had 
infections, 12.7% of infected patients had evidence of fungal 
infections with a case fatality of 30%. The majority of these were 
urinary, but the highest mortality was seen with fungaemia and 
peritonitis (case fatality >50%).41
Secondary bacterial peritonitis
A small proportion of patients with cirrhosis may develop peri-
tonitis secondary to perforation or inflammation of an intra- 
abdominal organ, known as secondary bacterial peritonitis. In 
a small retrospective analysis, secondary peritonitis represented 
4.5% of all peritonitis in cirrhotic patients.42 This should be 
suspected in those who have localised abdominal symptoms or 
signs, very high ascitic neutrophil count, the presence of multiple 
organisms on ascitic culture or in those with inadequate response 
to treatment.42 Cross- sectional imaging, such as CT, should be 
performed with early consideration of surgery in this scenario.
Antibiotic therapy
The most common organisms isolated in patients with SBP 
include Escherichia coli, Gram- positive cocci (mainly strepto-
coccus species) and enterococci. Empirical antibiotic therapy 
must be initiated immediately after the diagnosis of SBP.33 In the 
1990s, cefotaxime, a third- generation cephalosporin, was exten-
sively investigated in patients with SBP because it was found to 
cover 95% of organisms and high ascitic fluid concentrations 
could be achieved.43 44 The take home message from these 
studies is that matching an effective antibiotic to the cultured 
organism is key to successful treatment, rather than any apparent 
superiority of one drug over another. Since these studies, the 
landscape of bacterial resistance has significantly changed with 
an increase in antimicrobial resistant organisms,45 and there-
fore recommending a specific single empirical antibiotic is chal-
lenging. Thus, it is crucial to separate community- acquired SBP 
from healthcare- associated SBP (nosocomial – defined as infec-
tion >48 hours after hospital admission)46 and to consider both 
the severity of infection and the local resistance profile in order 
to decide the empirical antibiotic treatment of SBP.47 Over recent 
years there has been a significant increase in the number of infec-
tions caused by multidrug- resistant organisms,29 48 defined by 
an acquired non- susceptibility to at least one agent in three or 
more antimicrobial categories.49 It is also important to highlight 
the shift to extensively drug resistant bacteria, defined by non- 
susceptibility to at least one agent in all but two or fewer antimi-
crobial categories, or to pan- drug resistance bacteria, defined by 
non- susceptibility to all agents in all antimicrobial categories.49
A second diagnostic tap should be considered at 48 hours from 
starting treatment, to check the efficacy of antibiotic therapy in 
patients who have an apparently inadequate response. If ascitic 
fluid neutrophil count fails to decrease to less than 25% of the 
pretreatment value, this should raise suspicion of antibiotic resis-
tance or the presence of ‘secondary peritonitis’.33 50 Specialist 
microbiology links should be developed within each trust to help 
guide local policy and patient management and, in addition, 
de- escalation of anti- microbial agents according to susceptibility 
of positive cultures is recommended.
The evidence for the use of human albumin solution and 
recommendations for its use in SBP are discussed in a separate 
section below.
Prophylactic therapy for SBP
Three groups at high risk of developing SBP have been identified: (i) 
patients with acute gastrointestinal (GI) haemorrhage; (ii) patients 
with a low ascitic protein concentration and no prior history of 
SBP (primary prophylaxis) and (iii) patients with a previous episode 
of SBP (secondary prophylaxis).51 Although antibiotic prophy-
laxis to prevent further infection in patients presenting to hospital 
with upper GI bleeding is established in clinical practice,52–54 there 
remains uncertainty over prophylaxis in other circumstances. Addi-
tional studies related to this area after the Cochrane review53 are 
summarised in online supplemental table 1.
Primary prophylaxis
Primary prophylaxis is a controversial area and broad recom-
mendations are not straightforward. In 2016 the National 
Institute for Health and Care Excellence (NICE) recommended 
offering prophylactic oral ciprofloxacin or norfloxacin for 
people with cirrhosis and ascites and no history of SBP with 
an ascitic protein of ≤15 g/L (1.5 g/dL), until the ascites has 
resolved.55 Six studies were included in their analyses.56–61 The 
European Association for the Study of Liver (EASL) recommend 
primary prophylaxis with norfloxacin (400 mg/day) in patients 
with Child- Pugh score ≥9 and serum bilirubin ≥3 mg/dL, with 
either impaired renal function or hyponatraemia and ascitic fluid 
protein lower than 15 g/L.47 The American Association for the 
Study of Liver Diseases (AASLD) also suggest that antibiotics for 
primary prophylaxis of SBP should be considered for people at 
high risk of developing this complication, which was defined as 
an ascitic fluid protein <1.5 g/dL together with impaired renal 
function or liver failure.62
In contrast, in a large placebo- controlled randomised clin-
ical trial, the NORFLOCIR trial, norfloxacin did not reduce 
6- month mortality in patients with advanced cirrhosis, with 
>95% of patients included having no history of prior SBP.63 In 
post- hoc analyses, norfloxacin, appeared to increase survival of 
patients with low ascites fluid protein concentrations. However, 
other data have failed to replicate an association of incidence of 
SBP in patients with pre- existing low total ascitic fluid protein 
concentration in three large cohorts of hospitalised patients with 
cirrhosis and ascites.64 65 Furthermore, there are concerns about 
the potential consequences of long- term oral antibiotic therapy, 
including resistance, increased risk of Clostridium difficile 
associated diarrhoea, adverse reactions and drug interactions. 
In 2019 the Medicines and Healthcare products Regulatory 
Agency (MHRA) issued updated guidance on new restrictions 
and precautions for use of fluoroquinolone antibiotics following 
a detailed EU review of very rare reports of disabling and poten-
tially longlasting or irreversible side effects affecting the muscu-
loskeletal and nervous systems. Although SBP prophylaxis was 
not specifically considered, renal impairment is considered to 
increase this risk, and therefore healthcare professionals and 
patients should be vigilant during treatment with fluoroquino-
lone antibiotics and discontinue treatment at the first sign of 
tendon pain or inflammation. Finally, norfloxacin is not widely 
available in the UK.
In view of the uncertainties outlined above, we advocate 
primary prophylaxis is offered to patients considered at high 
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risk, as defined by an ascitic protein count <1.5 g/dL. However, 
it is important that the potential risks and benefits and existing 
uncertainties are communicated to patients.
It is expected that a large ongoing multicentre UK trial (Euro-
pean Union Drug Regulating Authorities Clinical Trials Data-
base Registration Number: 2019-000581-38) to investigate the 
efficacy of long- term co- trimoxazole compared with placebo as 
primary prevention for SBP may deal with these uncertainties.
Secondary prophylaxis
In patients who survive an episode of SBP, the cumulative recur-
rence rate at 1 year is approximately 70%.33 Probability of 
survival at 1 year after an episode of SBP is 30–50% and falls to 
25–30% at 2 years.66 67 There is only one randomised, double- 
blind, placebo- controlled trial of norfloxacin (400 mg/day) in 
patients who had a previous episode of SBP68; treatment reduced 
the probability of recurrence of SBP from 68% to 20%. A recent 
systematic review with meta- analysis concluded that rifaximin 
may be effective for both primary and secondary SBP prophylaxis 
compared with systemically absorbed antibiotics and compared 
with no intervention.69 However, additional prospective studies 
are required before a change in clinical practice can be recom-
mended. It has been suggested that proton pump inhibitor use 
may increase the risk for the development of SBP and indications 
for long- term use should be carefully assessed.70 71
We therefore recommend norfloxacin 400 mg once a day as 
secondary prophylaxis, although in view of limited availability in 
the UK, many centres use once daily ciprofloxacin 500 mg once 
a day as an alternative.
Recommendations
 ► Diagnostic paracentesis should be carried out without a 
delay to rule out SBP in all cirrhotic patients with ascites on 
hospital admission. (Quality of evidence: moderate; Recom-
mendation: strong)
 ► A diagnostic paracentesis should be performed in patients 
with GI bleeding, shock, fever or other signs of systemic 
inflammation, gastrointestinal symptoms, hepatic encepha-
lopathy, and in patients with worsening liver or renal func-
tion. (Quality of evidence: moderate; Recommendation: 
strong)
 ► Ascitic neutrophil >250/mm3 count remains the gold 
standard for the diagnosis of SBP and this can be performed 
either by manual microscopy or using automated counts, 
based on flow cytometry for counting and differentiating 
cells. (Quality of evidence: moderate; Recommendation: 
strong)
 ► Ascitic fluid culture with bedside inoculation of blood 
culture bottles should be performed to guide the choice 
of antibiotic treatment when SBP is suspected. (Quality of 
evidence: moderate, Recommendation: strong)
 ► Immediate empirical antibiotic therapy should be deter-
mined with due consideration of context of SBP (commu-
nity acquired or healthcare associated), severity of infection 
and local bacterial resistance profile. Cefotaxime has been 
widely studied, but choice of antibiotic should be guided by 
local resistance patterns and protocol. (Quality of evidence: 
moderate; Recommendation: strong)
 ► A second diagnostic paracentesis at 48 hours from the start 
of treatment to check the efficacy of antibiotic therapy 
should be considered in those who have apparently inad-
equate response or where secondary bacterial peritonitis 
is suspected. (Quality of evidence: low; Recommendation: 
weak)
 ► Patients presenting with gastrointestinal bleeding and under-
lying ascites due to cirrhosis should receive prophylactic 
antibiotic treatment (cefotaxime has been widely studied 
but the antibiotic should be chosen based on local data) 
to prevent the development of SBP. (Quality of evidence: 
strong, Recommendation: strong)
 ► Patients who have recovered from an episode of SBP should 
be considered for treatment with norfloxacin (400 mg once 
daily), ciprofloxacin (500 mg once daily, orally) or co- tri-
moxazole (800 mg sulfamethoxazole and 160 mg trimeth-
oprim daily, orally) to prevent further episode of SBP. 
(Quality of evidence: low; Recommendation: weak)
 ► Primary prophylaxis should be offered to patients consid-
ered at high risk, as defined by an ascitic protein count <1.5 
g/dL. However, it is important that the potential risks and 
benefits and existing uncertainties are communicated to 
patients. (Quality of evidence: low; Recommendation: weak)
DIETARY SALT RESTRICTION
There is little evidence to support salt restriction in patients 
with cirrhosis in absence of ascites. In patients with cirrhosis and 
ascites, seven RCTs and one cross- sectional survey have exam-
ined the role of salt restriction (online supplemental table 2).72–79 
One of the studies has only been published as an abstract.76 Four 
of the earlier RCTs72–75 found no difference in ascites control in 
those with and without salt restriction. Two recent RCTs found 
that a salt unrestricted diet (5–6.5 g/day) in contrast to a salt 
restricted diet (<5 g/day), resulted in ascites disappearance in a 
larger proportion (45% vs 16%) over a shorter time period and 
also significantly reduced the need for large volume paracentesis 
(LVP).77 78 Additionally, five of the eight above- mentioned studies 
reported significant adverse events with salt restriction, including 
hyponatraemia,72 77 reduced caloric intake,76 77 79 higher risk of 
renal impairment (0% vs 14%),77 hepatic encephalopathy (HE), 
hepatorenal syndrome (HRS), SBP78 and mortality.77 78 In a 
study by Sorrentino et al,78 1- year mortality was 45–60% (salt 
unrestricted diet) versus 82.5% (salt restricted diet).
Thus salt restricted diets (<5 g m of salt, <85 mmol sodium/
day) in patients with cirrhosis and ascites do not improve ascites 
control and, on the contrary, can result in complications. Addi-
tionally, such diets are difficult to comply with, especially since 
the average European ingests about 10 g of salt/day.80–82 A cross- 
sectional survey79 indicated that only about a third of cirrhotic 
patients were compliant with salt restriction, with an additional 
45% incorrectly stating that they were. Based on these data, 
patients with cirrhosis and ascites should have a moderately salt 
restricted diet, with daily salt intake of no more than 5–6.5 g 
(87 mmol–113 mmol sodium). This translates to a no added salt 
diet with avoidance of precooked meals. An ongoing systematic 
review is assessing the role of salt restriction in patients with 
ascites due to cirrhosis.83
Recommendations
 ► Patients with cirrhosis and ascites should have a moderately 
salt restricted diet with daily salt intake of no more than 
5–6.5 g (87 mmol–113 mmol sodium). This translates to 
a no added salt diet with avoidance of precooked meals. 
(Quality of evidence: moderate; Recommendation: strong)
 ► Patients with cirrhosis and ascites should receive nutritional 
counselling on the sodium content in the diet. (Quality of 
evidence: weak; Recommendation: strong)
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DIURETICS
Diuretics remain the main stay in management of ascites, though 
do not modify its natural history, providing only symptomatic 
benefit.47 Secondary aldosteronism plays a major role in renal 
sodium retention in patients with cirrhosis.84 Spironolactone is a 
specific pharmacological aldosterone antagonist, acting primarily 
through competitive binding of receptors at the aldosterone- 
dependent sodium–potassium exchange site in the distal convo-
luted renal tubule.85 Its hydrophilic derivative is potassium 
canrenoate. They are usually the first- line diuretics used,84 85 
either alone or in combination with a loop diuretic such as furo-
semide (causing sodium to flood more distal nephron sites).86 
Spironolactone appears to be more effective (response rate of 
95%) than furosemide (response rate of 52%) in non- azotemic 
patients with cirrhosis and ascites.87 88 Spironolactone has a 
long elimination half- life, allowing once a day dosing89–91; dose 
changes should occur no more frequently than every 3–4 days.86
In those who are intolerant to spironolactone an alternative 
diuretic is amiloride (acts in the collecting duct). However it is not 
as effective, an earlier RCT showing response rates of 35% vs 70% 
in those receiving amiloride versus potassium canrenoate, respec-
tively.92 Other diuretics which have been used in patients with 
cirrhosis and ascites include bumetanide93 and torasemide.94 95
Sequential versus combined therapy
Three RCTs assessing the role of sequential therapy (spironolactone 
followed by furosemide) or combination therapy (spironolactone 
plus furosemide) have given conflicting results (online supple-
mental table 3). In the first study,88 onset of diuresis was faster in 
the combination group than in the sequential group. The second 
RCT mostly included those with first presentation of ascites and 
found no difference in sequential versus combined therapy for the 
rapidity of ascites mobilisation and incidence of complications. 
However, a need for dose reductions was significantly higher in 
the combination group (68% vs 34%).96 The third RCT included 
almost two- thirds of patients with prior ascites.97 It reported shorter 
mean time for ascites resolution, lower risk of adverse events (espe-
cially hyperkalaemia), lower treatment failures (24% vs 44%), with 
ascites resolving in a higher percentage without need for diuretic 
dose change (76% vs 56%) in the combination versus sequential 
group, respectively.97
These conflicting results are explained by the heteroge-
neous patient population as studies by Angeli et al97 and Fogel 
et al88 included those with more advanced disease, explaining 
the lower response to spironolactone monotherapy. Others 
have also reported the likelihood of response to spironolac-
tone monotherapy (vs no response) if a first occurrence (56% 
vs 37%) rather than recurrent (44% vs 63%) or large ascites 
(16% vs 58%).98 Since in non- azotemic cirrhotic patients with 
ascites, the distal tubule reabsorbs almost all the sodium deliv-
ered, it is unsurprising that the administration of spironolactone 
alone results in a good natriuretic response in most.96 99 Another 
advantage of spironolactone monotherapy is its modest diuretic 
effect,86 as patients with cirrhosis are sensitive to compromises 
in their intravascular volume.91
Therefore, in patients with first presentation of moderate 
ascites, starting treatment with spironolactone monotherapy 
(starting dose 100 mg, increased to 400 mg) is reasonable. In 
those with persistent or severe ascites, and if faster diuresis 
is needed (for example, if hospitalised), it may be prudent to 
use combination therapy with spironolactone and furosemide 
(starting dose 40 mg, increased to 160 mg). Although maximal 
daily recommended doses of spironolactone and furosemide 
are 400 mg and 160 mg respectively,92 97 98 100 these are rarely 
achieved.88 96 In the largest study until now, which recruited 
about 2000 patients with ascites, at the time of discharge, mean 
diuretic units (one unit being 40 mg furosemide and 100 mg 
spironolactone) varied from 2.5+0.2 to 2.7+0.3.101
Based on evidence from an earlier RCT, it is recommended 
that diuretic- induced weight loss should not exceed 0.5 kg/day 
in patients without peripheral oedema, and 1 kg in the presence 
of peripheral oedema.47 100 Figure 3 summarises the stepped- up98 
approach to diuretic treatment.
Adverse reactions to diuretics
All patients initiating diuretics should be monitored for adverse 
events, the prevalence of which ranges from 19%96 to 33%.88 97 
Almost half with adverse events require diuretic discontinuation 
or dose reduction.88 In hospitalised patients treated with diuretics, 
hepatic encephalopathy is seen in up to 25%102 and renal impair-
ment in 14–20%,97 102 especially in the absence of peripheral 
oedema.100 Renal impairment is usually of moderate severity 
and is reversible on discontinuing diuretics.10 Hyponatraemia 
occurs in 8–30% and is related to impaired ability of the kidneys 
to excrete free water.10 97 Hypokalaemia is also a frequent side 
effect of loop diuretics.10 Similarly hyperkalaemia can occur in 
up to 11%.97
Gynaecomastia is commonly seen with spironolactone, espe-
cially with higher doses.86 It occurs less frequently with potas-
sium canrenoate (53% vs 100%).103 Eplerenone can also relieve 
the gynaecomastia.104 105
A causal relation is found between cirrhosis and muscle cramps, 
especially in advanced cirrhosis, with prevalence varying between 
26% and 72%,.106–108 The cirrhosis- induced arterial underfilling 
probably plays a role in the pathogenesis of cramps.107 Diuretics 
accentuate this reduction in effective plasma volume, thereby 
increasing the prevalence of cramps.107 An earlier systematic 
review (including only three RCTs) assessed various interven-
tions for muscle cramps, including zinc, 1-α-hydroxyvitamin 
D, vitamin E, branched chain amino acids, taurine, intravenous 
albumin and quinidine. Improvements occurred with most inter-
ventions with the exception of vitamin E.109 Recent RCTs have 
reported beneficial effects with methocarbamol,110 taurine111 
and baclofen.112
Monitoring of diuretics
The aim of diuretic therapy is to ensure that urinary sodium excre-
tion exceeds 78 mmol/day (88 mmol intake per day – 10 mmol 
non- urinary excretion per day).62 113 A random spot urine sodi-
um:potassium ratio between 1.8 and 2.5 has a sensitivity of 87.5%, 
specificity of 56–87.5% and accuracy of 70–85% in predicting a 
24- hour urinary sodium excretion of 78 mmol/day.114 115
Hyponatraemia
Recent guidelines define hyponatraemia as a serum sodium 
<135 mmol/L, with 130–135 mmol/L, 125–129 mmol/L and 
<125 mmol/L, constituting mild, moderate and severe hypona-
traemia, respectively.47 116 A prospective population survey among 
patients with cirrhosis found serum sodium <130 mmol/L in 
21.6%.117 Hyponatraemia has been associated with higher preva-
lence of refractory ascites, hepatic encephalopathy, SBP, HRS and 
mortality.117–119 Acknowledging this, the Model for End Stage Liver 
Disease (MELD) score now incorporates serum sodium (MELD- 
Na).120 Those with cirrhosis and chronic hyponatraemia are often 
asymptomatic and seldom need treatment.62
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Both hypovolaemic and hypervolaemic hyponatraemia is 
observed in cirrhosis.47 Hypovolaemic hyponatraemia results 
from overzealous diuretic therapy, being characterised by a 
prolonged negative sodium balance with marked loss of extra-
cellular fluid. Its management requires expansion of plasma 
volume with normal saline and cessation of diuretics.47 Most 
hepatologists would discontinue diuretics if serum sodium is 
<125 mmol/L.
A number of studies (which include four RCTs and a retro-
spective cohort study) have assessed role of intravenous (IV) 
human albumin solution (HAS) in patients with hyponatraemia 
(online supplemental table 4).121–126 These studies did not 
strictly stratify patients as having hypovolaemic hyponatraemia 
and mostly included those with Child C cirrhosis and refrac-
tory ascites undergoing LVP. There were differences in baseline 
serum sodium levels, use of diuretics, and degree of salt and 
fluid restriction. Therefore not unsurprisingly results have been 
conflicting. An earlier meta- analysis that included three of the 
above RCTs123–125 reported that use of IV HAS versus no IV HAS 
reduced occurrence of hyponatraemia (3.9% vs 16.5%) but did 
not affect mortality.127 A later meta- analysis (IV HAS vs no IV 
HAS) which included only two RCTs123 124 found no beneficial 
effects on hyponatraemia or mortality.128 In the retrospective 
cohort study among hospitalised patients with hyponatraemia 
(only 42% requiring inpatient LVP), those receiving IV HAS 
were more likely to have resolution of hyponatraemia than those 
who did not (85.41% vs 44.78%).126 Hyponatraemia resolution 
was an independent predictor of 30- day survival, even after 
adjustment for admission sodium and glomerular filtration rate. 
At present, however, there is insufficient evidence to routinely 
recommend IV HAS outside of a LVP setting in patients with 
cirrhosis and ascites and hypovolaemic hyponatraemia.
Hypervolaemic hyponatraemia is more common in cirrhosis, 
occurring owing to non- osmotic hypersecretion of vasopressin 
and enhanced proximal nephron sodium reabsorption with 
impaired free water clearance, both being caused by effective 
hypovolaemia.47 129 Impaired free water clearance is observed in 
about 60% of patients with cirrhosis.130
Hypervolaemic hyponatraemia requires a negative water 
balance.47 Many hepatologists do recommend fluid restriction 
of between 1 and 1.5 L/day in presence of severe hyponatraemia 
(serum sodium <125 mmol/L). However, there are few data 
to support the level of serum sodium at which to initiate fluid 
restriction and how much fluid to restrict. It is sodium restric-
tion and not fluid restriction that results in weight loss as fluid 
passively follows the sodium.62 113 131 Although fluid restriction 
may be helpful in preventing further decrease in serum sodium, 
it only rarely improves it. This is because on a practical level, 
fluid restriction to <1 L /day is not tolerated.129 Water restriction 
should be reserved for those who are clinically hypervolaemic 
Figure 3 Approach to the use of diuretics in the management of ascites in patients with cirrhosis.
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with severe hyponatraemia (serum sodium <125 mmol/L) with 
normal serum creatinine and not currently receiving diuretics. 
These recommendations are based on our consensus and consis-
tent with our earlier guidelines.132 It is also our consensus that 
fluid restriction is unnecessary in absence of hyponatraemia.
Hypertonic sodium chloride (3%) administration may 
improve hyponatraemia at the cost of worsening fluid over-
load. It is best reserved for those with severely symptomatic 
acute hyponatraemia, especially if a transplant is imminent.47 To 
prevent rapid increase in serum sodium and the risk of devel-
oping central pontine myelinolysis,133 guidelines recommend a 
serum sodium increase of up to 5 mmol/L in the first hour with a 
limit of 8–10 mmol/L every 24 hours thereafter until the serum 
sodium concentration reaches 130 mmol/L.47 116 134 135
Vaptans
Vaptans are vasopressin antagonists that competitively bind 
and block the V2- receptors of arginine vasopressin in the renal 
collecting ducts and induce a highly hypotonic diuresis without 
affecting the excretion of electrolytes.136 In three RCTs involving 
1200 patients, satavaptan was no more effective than placebo in 
controlling ascites and need for LVPs, though it improved serum 
sodium concentration in those with hyponatraemia.137 Two of 
the studies were terminated owing to an increase in serum bili-
rubin, higher mortality (31% vs 22%), mostly due to increased 
cirrhosis complications and other adverse events.137 Two meta- 
analyses138 139 on vaptans in cirrhosis reported improved serum 
sodium levels and ascites mobilisation, but without a beneficial 
effect on cirrhosis- related complications or mortality (RR=1.06, 
95% CI 0.90 to 1.26). Current evidence does not support 
routine use of vaptans in cirrhosis.
Midodrine
Portal hypertension and splanchnic vasodilatation are major 
contributors to the development of ascites.7 In fact, mean arterial 
pressure and plasma norepinephrine are two of the best predic-
tors of prognosis in ascites.140 Therefore, vasopressors such as 
midodrine, an α-adrenergic agonist, have been used in non- 
azotemic patients with ascites, resulting in significant increase in 
mean arterial pressure and urine sodium excretion and signifi-
cant decreases in plasma renin and aldosterone.141
A small RCT in patients with refractory ascites (midodrine 7.5 
mg three times a day vs standard medical therapy) showed that at 
3 months 94% versus 50% had a complete/partial ascites control, 
with a trend for a survival benefit in the midodrine group.142 In 
another small RCT (midodrine vs placebo), significant reduc-
tion in body weight and abdominal girth was observed after 2 
weeks of midodrine therapy.143 Though larger RCTs are needed 
to confirm these findings, it may be appropriate to consider use 
of midodrine in refractory ascites on a case- by- case basis.
Recommendations
 ► In patients with the first presentation of moderate ascites 
spironolactone monotherapy (starting dose 100 mg, 
increased to 400 mg) is reasonable. In those with recurrent 
severe ascites, and if faster diuresis is needed (for example, 
if the patient is hospitalised), combination therapy with 
spironolactone (starting dose 100 mg, increased to 400 mg) 
and furosemide (starting dose 40 mg, increased to 160 mg) is 
recommended. (Quality of evidence: moderate; Recommen-
dation: strong)
 ► All patients initiating diuretics should be monitored for 
adverse events. Almost half of those with adverse events 
require diuretic discontinuation or dose reduction. (Quality 
of evidence: low; Recommendation: weak)
 ► Hypovolaemic hyponatraemia during diuretic therapy 
should be managed by discontinuation of diuretics and 
expansion of plasma volume with normal saline. (Quality of 
evidence: low; Recommendation: weak)
 ► Fluid restriction to 1–1.5 L/day should be reserved for those 
who are clinically hypervolaemic with severe hyponatraemia 
(serum sodium <125 mmol/day). (Quality of evidence: low; 
Recommendation: weak)
 ► Hypertonic sodium chloride (3%) administration should be 
reserved for those who are severely symptomatic with acute 
hyponatraemia. Serum sodium should be slowly corrected. 
(Quality of evidence: low; Recommendation: weak)
 ► It may be appropriate to consider use of midodrine in refrac-
tory ascites on a case- by- case basis. (Quality of evidence: 
low; Recommendation: weak)
LARGE VOLUME (THERAPEUTIC) PARACENTESIS
Large volume paracentesis (LVP) is the standard of care for 
managing large volume ascites both in conjunction with diuresis 
to relieve symptoms of a tense abdomen, as well as in the manage-
ment of refractory ascites, when diuretics become ineffective or 
the side effects preclude their continued use. Development of 
refractory ascites is of prognostic significance,144 therefore, at its 
onset, suitability of liver transplantation should be considered 
and assessed as a priority.
Performance standards
An efficient LVP service can be provided safely in a day case 
or outpatient setting and non- physician healthcare providers 
such as GI endoscopy assistants145 and specialist nurses146 can be 
trained to perform therapeutic paracentesis and lead the service 
effectively. Exemplar training programmes indicate that 10 
supervised procedures would be optimal for training to achieve 
competence in performing therapeutic paracentesis; mean dura-
tion of LVP was 97±24 min, and the mean volume of ascitic 
fluid removed was 8.7±2.8 L.145
Patients should provide informed consent before the procedure. 
In 52 patients (15% obese) with ascites due to cirrhosis, ultra-
sound demonstrated that the left lower quadrant abdominal wall 
was thinner and depth of ascites greater, therefore, a suitable site 
for drain insertion.147 To minimise the risk of injury to the inferior 
epigastric artery (and avoid the liver and spleen) during paracen-
tesis, point of puncture should be at least 8 cm from the midline and 
5 cm above the symphysis148–150 (figure 4). All ascitic fluid should 
be drained to dryness in a single session as rapidly as possible over 
1–4 hours assisted by gentle mobilisation of the cannula or turning 
the patient onto their side, if necessary. After the paracentesis, the 
patient should lie on the opposite side for 2 hours if there is leakage 
of any remaining ascitic fluid, and/or a suture (ideally purse- string) 
inserted around the site of drainage. These steps help to minimise 
the risk of ascitic fluid leakage.
Adverse events
A systematic review of adverse events that can result from a para-
centesis reported an overall rate of significant bleeding ranging 
from 0% to 2.7%, ascitic fluid leak in 0% to 2.35%, perforation 
in 0.83%, residual catheter tip fragment in 0.41% and death in 
0% to 17% among studies that were heterogeneous.18 In a retro-
spective study published in abstract form, of consecutive 3116 
ultrasound guided LVPs, the mean international normalised 
ratio (INR) was 2.1 (range 1.0–7.0) and MELD score 24 (range 
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6–40) for inpatients, and 1.5 (range 1‐5–5) and 16 (range 
5–40) for outpatients, respectively. With no patients receiving 
fresh frozen plasma (FFP) before the procedure, a total of six 
patients (0.19%) had post‐LVP bleeding requiring blood trans-
fusion (one inpatient, five outpatients) and one required angiog-
raphy with embolisation of a bleeding abdominal wall vessel. No 
patient died.151 In another study where GI endoscopy assistants 
performed 1100 large volume paracenteses, with a preprocedure 
mean INR of 1.7 (range 0.9–8.7) and the mean platelet count 
was 50.4×109/L (range, 19–341×109/L), there were no signifi-
cant procedure- related complications.145
Risk factors for haemorrhagic complications after paracen-
tesis in three studies (which included patients with acute on 
chronic liver failure) were high MELD and Child- Pugh scores 
and renal impairment.152–154 In a study by Hung et al, acute 
kidney injury at he time of paracentesis was the only indepen-
dent predictor of post- paracentesis haemoperitoneum, inde-
pendent of MELD score, large volume paracentesis, sepsis, 
platelets, INR and haemoglobin levels.153 While some patients 
with bleeding complications after paracentesis have low platelet 
counts, elevated INR and low fibrinogen levels, this is invari-
ably accompanied with high MELD scores (>25) and/or renal 
impairment.152 154
Ultrasound guidance
Use of ultrasound guidance may reduce the adverse events related 
to LVP.155 In a study involving 1297 procedures, 723 (56%) with 
ultrasound guidance and 574 (44%) without where the indica-
tions for paracentesis were similar between the two groups, the 
incidence of adverse events was lower in the ultrasound- guided 
procedures.156 In another retrospective cohort study, 0.8% of 
565 patients undergoing paracentesis experienced bleeding 
complications. After adjustment, ultrasound guidance was asso-
ciated with lower risk of bleeding complications by 68%.157
Recommendations
 ► Patients should give informed consent for a therapeutic or 
diagnostic paracentesis. (Quality of evidence: low; Recom-
mendation: strong)
 ► Ultrasound guidance should be considered when available 
during LVP to reduce the risk of adverse events. (Quality of 
evidence: low; Recommendation: weak)
 ► Routine measurement of the prothrombin time and platelet 
count before therapeutic or diagnostic paracentesis and infu-
sion of blood products are not recommended. (Quality of 
evidence: moderate and Recommendation: strong)
USE OF HUMAN ALBUMIN SOLUTION (HAS)
Plasma expansion after paracentesis
One study evaluating haemodynamic and neurohumoral 
responses in 12 patients after a single, 5 L total paracentesis 
concluded that it was safe to omit albumin in these patients.158 
However, a subsequent study including 80 patients with acute 
on chronic liver failure (ACLF) found that albumin significantly 
reduced complications (renal impairment, hyponatraemia and 
death) following <5 L paracentesis compared with no admin-
istration of fluid.159 Thus in <5 L paracentesis we recommend 
that plasma expansion is not necessary, unless there is evidence of 
ACLF. This recommendation is based on consensus rather than 
evidence and is consistent with other international guidance.47
Plasma volume expansion should always be used for LVP with 
>5 L of ascites removed. Serial paracenteses with and without 
albumin replacement have been evaluated in patients with tense 
ascites.123 124 There was a higher rate of renal impairment, fall in 
serum sodium levels, and a marked activation of the renin–angio-
tensin–aldosterone system in those not treated with albumin. 
However, the pooled risk ratio from these studies, which are 
more than 25 years old, showed only a tendency toward benefit 
of albumin (pooled RR=0.23, 95% CI 0.03 to 1.64) (online 
supplemental table 5). The consensus is that volume expansion 
Figure 4 Anatomical landmarks for the safe performance of paracentesis [A] and performance of ascites drainage in patients with large ascites [B].
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should be used with LVP. We recommend large volume paracen-
tesis in one session and discourage repeated low volume para-
centesis, which offers no additional benefits and carries a higher 
risk of procedure- related complications.
Some debate remains over the use of albumin or artificial 
plasma expanders for volume expansion. Pooled analysis of 
10 studies160–169 found that cirrhotic patients undergoing para-
centesis who received albumin were no less likely to develop 
renal dysfunction than patients undergoing paracentesis that 
received an alternative plasma expander (pooled RR=1.11, 
95% CI 0.58 to 2.14) (online supplemental table 5). Analysis 
from two other independently conducted systematic reviews is 
consistent with these findings.127 128 Pooled analysis from eight 
studies160 162–164 166 167 169 170 found that cirrhotic patients under-
going paracentesis who received albumin were no less likely to die 
than those who received an alternate plasma expander (pooled 
RR=0.83, 95% CI 0.61 to 1.12) (online supplemental table 6), 
which is supported by two systematic reviews.127 128 However, 
when all comparators to albumin (including control and vasocon-
strictor alone) are pooled (16 RCTs) the RR is 0.77 (95% CI 0.57 
to 1.00). This translates to 57 to 100 fewer patients per 1000 
dying after LVP when HAS is used (online supplemental table 6).
Less clinically important outcomes have been shown to improve 
in patients treated with HAS versus other plasma expanders. 
There is a decreased incidence of post- paracentesis- induced 
circulatory dysfunction (defined as a decrease in plasma renin) 
in patients undergoing LVP treated with albumin compared with 
an alternative plasma expander in a meta- analysis containing 
eight RCTs127 (OR=0.34, 95% CI 0.23 to 0.51), and a pooled 
decrease in hyponatraemia in nine RCTs (OR=0.61, 95% CI 
0.40 to 0.93).127 Both are supported in a second independently 
conducted systematic review.128
Most of the plasma expanders used in the described studies 
are no longer in use and have been restricted by the European 
Medicines Agency (eg, polygeline carries risk of prion trans-
mission, dextran the risk of allergic reaction and hydroxyethyl 
starch association with renal impairment and deranged coagu-
lation). Therefore, consensus is that volume expansion should 
be with HAS due to availability, familiarity of use and suggested 
benefits in the available studies.
Two small prospective RCTs compared standard dose (6–8 
g/L of ascites drained) albumin after LVP with low- dose albumin 
(2–4 g/L).171 172 Pooled results from 70 patients suggested no 
difference in post- paracentesis- induced circulatory dysfunction 
(RR=2.97, 95% CI 0.89, 9.91) and no development of renal 
dysfunction (no events in either group). A larger retrospective 
review of 935 patients found no increase in renal dysfunction 
when adherence to guidance (8 g/L after 5 L drained) was imple-
mented,173 but significant cost savings were made because less 
HAS was used.
Potential cost savings have been proposed in relation to length 
of hospital stay in patients with ascites undergoing LVP who 
are treated with HAS as compared with an alternative plasma 
expander.166 However, HAS is more expensive than alternatives 
and is in worldwide shortage, therefore it should be prescribed 
according to recommended guidance based on the available 
evidence.174 There have been no cost- effectiveness analyses in 
the UK.
Until further studies are undertaken to compare efficacy of 
albumin against clinically available artificial plasma expanders, 
we would recommend that albumin remains the preferred 
plasma expander when paracentesis is undertaken. Albumin (as 
20% or 25% solution) should be infused after paracentesis of 
>5 L is completed at a dose of 8 g albumin/L of ascites removed.
Albumin infusion in SBP
Renal impairment develops in up to 30% of patients with SBP 
and is one of the strongest predictors of mortality,175 176 along-
side progressive liver dysfunction. Three studies176–178 have 
compared albumin with no intervention, and one RCT179 
compared albumin with a plasma expander in order to prevent 
the development of renal impairment in patients with SBP. 
Cirrhotic patients with SBP treated with albumin were 72% less 
likely to develop renal dysfunction than patients with SBP who 
did not receive albumin (288 patients, pooled RR=0.28, 95% 
CI 0.16 to 0.50) (online supplemental table 7). There was also a 
decrease in mortality in patients with SBP treated with albumin, 
with patients 47% less likely to die than those not receiving 
albumin (334 patients, pooled RR=0.53, 95% CI 0.36 to 0.79) 
(online supplemental table 8). Therefore, we recommend the use 
of albumin in patients with SBP to prevent the development of 
renal dysfunction and decrease mortality.
Although patients with SBP have a higher risk of post- drain 
renal dysfunction, LVP is not contraindicated. Therefore, if LVP 
is indicated in a patient with SBP then this should proceed with 
HAS support. The dose of albumin in original studies was 1.5 
g albumin per kg body weight within 6 hours of diagnosis and 
1.0 g/kg on day 3, using estimated dry weight, which is often 
difficult in cirrhotic patients. Some small studies have suggested 
that lower doses of albumin are as effective in preventing renal 
dysfunction and mortality in SBP,180 181 and one retrospective 
review including 88 patients with SBP suggested that doses of 
HAS in excess of 87.5 g (>4×100 mL 20% HAS) are associated 
with a worse outcome, possibly secondary to fluid overload.182 
Fluid overload has been reported in prospective studies of 
albumin in patients with cirrhosis and non- SBP infection.183 184 
Therefore, if patients have an increased serum creatinine or a 
rising serum creatinine, we recommend 1.5 g albumin/kg within 
6 hours of diagnosis, followed by 1 g/kg on day 3.
Long term regular outpatient HAS therapy
Improving morbidity and mortality by long- term administration 
of albumin to patients with decompensated cirrhosis and ascites 
has been explored in six studies with three recent RCTs, in 
contrasting patient groups, with contradictory findings (online 
supplemental table 9).185–190
In the ANSWER185 study, 431 patients with uncomplicated 
ascites receiving diuretics were randomised to weekly outpa-
tient HAS infusions or no additional intervention (standard 
medical therapy). The study had a pragmatic approach and was 
unblinded. Overall 18- month survival was significantly higher 
in the standard therapy plus HAS than in the standard medical 
therapy group (Kaplan- Meier estimates 77% vs 66%; p=0.028), 
resulting in a 38% reduction in the mortality hazard ratio (0.62, 
95% CI 0.40 to 0.95). There were additional benefits with lower 
incidence rate ratio (IRR) for infection (SBP and non- SBP) and 
renal dysfunction. However, unlike the standard therapy group, 
the HAS group had weekly medical professional contact when 
IV albumin was administered which could possibly have caused a 
confounding effect by improving standard of care in this group.
In the MACHT186 study, a double- blind, placebo- controlled 
trial, patients with advanced cirrhosis (MELD score 17–18) 
awaiting liver transplantation received outpatient fortnightly 
treatment with midodrine and albumin. This slightly suppressed 
vasoconstrictor activity but did not prevent complications of 
cirrhosis or improve survival. However, only nine patients were 
treated for the entire year, the median length of treatment was 
only 80 days and the mortality rate in both arms was very low 
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due to patients undergoing timely liver transplantation. Perhaps, 
therefore, a greater dose of albumin or longer duration of treat-
ment is required to benefit patients and should be targeted at 
those who are not close to receiving a liver transplant.
Di Pascoli et al190 most recently published outcomes of a study 
of 45 patients with refractory ascites undergoing regular LVP who 
accepted 20 g twice weekly albumin plus diuretics and sodium 
restriction versus 25 patients who did not (non- randomised, 
single centre, not blinded). Cumulative incidence of mortality 
was 41.6% in the albumin group versus 65.5% in the standard of 
care group. Albumin- treated patients had a lower probability of 
hospitalisation. There were no differences in the number of LVPs 
performed. Follow- up was 400 days in the albumin group and 
318 in the standard of care group. Although the study was non- 
randomised (patient choice to treatment arm) it does provide 
some additional evidence that using albumin in a longer- term 
outpatient setting may be beneficial, as in the ANSWER study, 
even in patients with very advanced disease. Two older studies 
support the use of outpatient albumin therapy in decreasing 
hospital admissions and LVP requirement with conflicting results 
on mortality.187 189
We expect these studies to stimulate further investigation to 
determine whether long- term albumin administration is feasible, 
efficacious and cost- effective in patients with cirrhosis and ascites 
within the NHS. Further research is required to determine which 
patients could benefit most from treatment, which seems to be 
those with less advanced disease who could receive treatment for 
at least 12 months. At present it is not possible to recommend 
the use of outpatient albumin administration in patients with 
ascites due to cirrhosis.
Recommendations
 ► Albumin (as 20% or 25% solution) should be infused after 
paracentesis of >5 L is completed at a dose of 8 g albumin/L 
of ascites removed. (Quality of evidence: high; Recommen-
dation: strong)
 ► Albumin (as 20% or 25% solution) can be considered 
after paracentesis of <5 L at a dose of 8 g albumin/L of 
ascites removed in patients with ACLF or high risk of post- 
paracentesis acute kidney injury. (Quality of evidence: low; 
Recommendation: weak)
 ► In patients with SBP and an increased serum creatinine 
or a rising serum creatinine, infusion of 1.5 g albumin/kg 
within 6 hours of diagnosis, followed by 1 g/kg on day 3, 
is recommended. (Quality of evidence: low; Recommenda-
tion: weak)
TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC STENT 
SHUNT (TIPSS)
TIPSS decompresses the portal system by creating an artificial 
communication between the portal and the hepatic vein. TIPSS 
results in an increase in cardiac output and decrease in systemic 
vascular resistance in the short term.191–193 Consequently, TIPSS 
leads to improvement in effective hypovolaemia and renal func-
tion, resulting in increased urinary sodium excretion.191–195 
The increase in urinary sodium correlates with the reduction in 
plasma renin activity.195 196
The efficacy of TIPSS in the management of ascites has 
been compared with LVP in seven RCTs (online supple-
mental table 10).194 197–202 The first six trials used bare metal 
stents. Shunt dysfunction due to stent stenosis or thrombosis 
is a common complication of bare stents and develops in up 
to 80% of patients.199 201 The use of polytetrafluoroethylene 
(PTFE)- covered stents has significantly increased the long- term 
patency of the stent to 92% at 1 year and 89% at 2 years.202–204
TIPSS controls ascites better than LVP. Patients treated with 
TIPSS are more likely to be free of recurrent ascites than those 
treated with LVP at 12 months.205 However, the impact of TIPSS 
on survival is less consistent. The initial trial by Lebrec et al194 
showed a better survival with LVP mainly due to the detrimental 
effect of TIPSS in Child- Pugh C patients. The subsequent three 
studies did not show any difference in survival between TIPSS 
and LVP,197–199 whereas the most recent three studies have shown 
improved survival with TIPSS.200–202 In the two meta- analyses 
of the six trials using bare stent grafts, Bai et al205 reported an 
improved transplant- free survival with TIPSS but this was limited 
to patients with recurrent ascites and not refractory ascites in the 
other study.206 All the six trials with bare metal stents consis-
tently showed that TIPSS resulted in higher incidence of hepatic 
encephalopathy than with LVP.
PTFE- covered stents are now standard of care, and hence the 
results of the historical RCTs using bare stents are less relevant. 
Only the most recent RCTs compared PTFE- covered stent with 
LVP in patients with recurrent ascites. It demonstrated improved 
1- year survival with TIPSS without any increased incidence of 
hepatic encephalopathy.202
TIPS has also been shown to improve the quality of life and 
nutritional status in patients with refractory ascites,207–209 but 
the improvement was dependent on the resolution of ascites.
TIPSS technique
A controlled study comparing TIPSS with 8 mm and 10 mm 
covered stent was stopped early as the 8 mm stent was not effec-
tive in controlling portal hypertensive complications (variceal 
bleeding and ascites).210 The rate of hepatic encephalopathy was 
equal between the two groups. However, in another study of 
variceal bleeding, 8 mm stents were as effective as 10 mm stents 
in preventing rebleeding, with a 50% reduction in the incidence 
of encephalopathy with 8 mm stents.211 Nonetheless, the appli-
cability of these data in patients with refractory ascites is unclear, 
and evidence suggests that stent diameter increases over time.212 
In a retrospective study of patients with refractory ascites, 10 
mm covered stent led to better control of ascites than an 8 mm 
stent, without any increase in encephalopathy.213 Data from 
recent TIPSS registry in Germany reported an improved survival 
with 8 mm than with 10 mm covered stent.214 The optimal diam-
eter of covered TIPS stent in refractory ascites remains unclear.
The volume of TIPSS being performed in an individual hospital 
influences outcomes. Inpatient mortality was significantly lower 
in centres performing more than 20 TIPS procedures per year.215
Patient selection
Careful selection of patients with refractory ascites to be treated 
with TIPSS is vital to maximise the benefits and reduce the 
harmful effects of the treatment. The exclusion criteria for the 
insertion of TIPSS in the seven RCTs are reported in online 
supplemental table 10.
Patients with advanced stages of cirrhosis have been excluded 
from the trials as indicated by serum bilirubin,197–202 prolonged 
prothrombin time,198 199 renal dysfunction194 197 198 200–202 and 
Child- Pugh score.200–202 Presence of chronic hepatic encephalop-
athy was an exclusion criterion in all the RCTs; the presence of 
pre- TIPS encephalopathy has been shown to be a predictor of 
poor outcome following TIPSS.216–218
In retrospective studies, patients with advanced disease had 
a worse outcome following TIPS insertion. The MELD score 
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was originally developed to predict survival following TIPSS 
and included serum creatinine, bilirubin, INR and aetiology 
of cirrhosis.219 The MELD score has now evolved into a prog-
nostic score in patients with cirrhosis.220 Among patients with 
refractory ascites treated with TIPSS with covered stent, 1- year 
survival is 84% in those with MELD score <15 compared with 
54% for MELD score >18.221 In refractory ascites, a simple 
model of serum bilirubin and platelet count has been shown 
to predict 1- year survival.222 The survival rate of patients with 
serum bilirubin >50 µmol/L or platelet count of <75×109/L 
was only 31.2% compared with 73.1% in patients with serum 
bilirubin <50 µmol/L and platelet count of >75×109/L. The 
exact survival rate quoted here has to be interpreted cautiously 
as earlier patients in the cohort were treated with a bare metal 
stent before the introduction of a PTFE- covered stent. Hypo-
natraemia has also been shown to be related poor survival 
following TIPSS,223 but subsequent studies have not reproduced 
this finding.221 224 Up to 50% of patients with decompensated 
cirrhosis have sarcopenia, which in turn negatively affects clinical 
outcome in these patients. However, the direct impact of sarco-
penia on outcomes following TIPSS is unclear. Sarcopenia has 
been shown to be independently associated with development of 
post- TIPSS encephalopathy, but this study included patients with 
refractory ascites and uncontrolled variceal bleeding.225 A recent 
retrospective study published in abstract form on patients under-
going TIPSS for refractory ascites reported no impact of sarco-
penia on outcomes after TIPSS.226 Furthermore, they reported 
an improvement in muscle mass following TIPSS insertion.
Although increasing age has been associated with poorer 
survival following TIPSS,215 227 228 the mean age in these studies 
was between 54 and 57 years. Patients above the age of 70 were 
generally excluded from the previously mentioned RCTs. There 
is a lack of data in the literature for clinical outcome following 
TIPS in older patients (>70 years). Interestingly, functional 
disability as measured by patient- reported activities of daily 
living predicts post- TIPSS mortality adjusted for MELD score.229
The management of hepatic encephalopathy after TIPSS is 
beyond the scope of this document and is discussed in the recent 
BSG/BASL TIPSS guidelines.
Recommendations
 ► TIPSS should be considered in patients with refractory 
ascites. (Quality of evidence: high; Recommendation: strong)
 ► Caution is required if considering TIPSS in patients with 
age >70 years, serum bilirubin >50 µmol/L, platelet count 
<75×109/L, MELD core ≥18, current hepatic encephalop-
athy, active infection or hepatorenal syndrome. (Quality of 
evidence: moderate; Recommendation: strong)
MANAGEMENT OF UMBILICAL HERNIA IN PATIENTS WITH 
ASCITES
In the cirrhotic patient, the incidence of abdominal wall hernia is 
16% and reaches 24% in the presence of ascites; more than half 
of these are umbilical hernias.230 These progressively enlarge 
and are prone to complications, including ulceration of the 
overlying skin, incarceration, strangulation, and rupture. Non- 
operative management of complicated hernias with antibiotics 
and dressing changes might result in mortality rates in the range 
of 60–88%.231 On the other hand, hernia repair in cirrhosis 
has often been avoided due to high postoperative morbidity 
and mortality. Emergency surgery (OR=10.32, 95% CI 3.66 
to 47.82), Child- Pugh- Turcotte class C (OR=5.52, 1.67 to 
32.45), American Society of Anaesthesiologists (ASA) score ≥3 
(OR=8.65, 3.65 to 87.23) and MELD score ≥20 (OR=2.15, 
2.71 to 32.68) are associated with mortality.232
A recent retrospective series of 102 patients, who underwent 
surgical repair of the umbilical hernia in the presence of ascites, 
included 45 patients having emergency surgery (24 with incar-
ceration, 12 with rupture of the hernia sac, and nine with skin 
ulceration or necrosis). Morbidity and mortality rates of 37.2% 
and 3.9%, respectively, were observed.233 Optimising manage-
ment of ascites, including LVP and TIPSS perioperatively, could 
reduce the risk of wound dehiscence and recurrence of hernia.234
Recommendations
 ► Suitability and timing of surgical repair of umbilical hernia 
should be considered in discussion with the patient and 
multidisciplinary team involving physicians, surgeons and 
anaesthetists. (Quality of evidence: low; Recommendation: 
strong)
HEPATIC HYDROTHORAX
Hepatic hydrothorax (HH) is accumulation of transudative 
fluid in the pleural space in the absence of cardiac, pulmonary 
or pleural disease, affecting approximately 5–12% of patients 
with advanced liver disease.235 The first- line management of 
hydrothorax is based on controlling ascites with diuretics and/
or LVP as discussed previously. However, pleural effusion can 
persist despite successful treatment of ascites, defined as refrac-
tory hydrothorax.47
Therapeutic thoracentesis is required to provide symptom-
atic relief from dyspnoea but the effect is transient. Repeated 
procedures increase the risks of complications, including pneu-
mothorax, bleeding and pleural infection.236 TIPSS has been 
suggested either as a definitive treatment or as a bridge to 
transplantation in patients with refractory hydrothorax. Meta- 
analysis of six retrospective studies with a total of 198 patients 
reported a response rate of 56%.237 Mortality within 45 days 
of TIPSS placement was 18%, mainly related to older age and 
the severity of liver disease. However, without any data on 
comparison with standard treatment, it is difficult to interpret 
the impact of TIPSS on survival. It is also worth noting that only 
one of these studies reported on patients treated with PTFE- 
covered stents.238 In patients with contraindications to TIPSS or 
liver transplant, a permanent indwelling pleural catheter can be 
considered in conjunction with the patient and the multidisci-
plinary team taking into account the infection risk.
Recommendation
 ► TIPSS should be considered in patients with HH after discus-
sion with the multidisciplinary team. (Quality of evidence: 
low; Recommendation: strong)
 ► In patients with HH who are not undergoing a TIPSS and/
or a liver transplant evaluation, alternative palliative inter-
ventions should be considered. (Quality of evidence: low; 
Recommendation: strong)
NON-SELECTIVE BETA-BLOCKERS AND ASCITES
The portal pressure- lowering effects of non- selective beta- 
blockers (NSBB) have been known to be beneficial in patients 
with ascites for three decades. Lebrec’s group demonstrated back 
in 1991 in a meta- analysis of trial data that NSBB reduce the 
likelihood of first variceal haemorrhage in the ascites subgroup, 
while in Child’s Pugh B and C cirrhosis the addition of NSBB 
to band ligation results in less variceal rebleeding and superior 
survival.239 240 Proven haemodynamic response to NSBB (drop 
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in hepatic venous pressure gradient (HVPG) of ≥10–20% from 
baseline, or to <12 mm Hg) has been linked with a lower proba-
bility of the development of ascites; and in patients already with 
ascites, a lower probability of refractory ascites and hepatorenal 
syndrome.241 242 However, it remains possible that non- response 
in this context is simply a surrogate marker for disease severity.
In recent years, there has been increasing recognition that the 
benefits of NSBB in patients with cirrhosis may not be exclu-
sively explained by the reduction in portal pressure. NSBB 
reduce markers of intestinal permeability, bacterial transloca-
tion, systemic inflammation and the incidence of spontaneous 
bacterial peritonitis independently of haemodynamic response, 
suggesting a direct effect, potentially via intestinal transit time 
or on the bowel mucosal integrity.243–245 Given the mounting 
evidence that bacterial translocation and the systemic inflamma-
tory response contribute to the downward spiral of circulatory 
dysfunction in cirrhosis, it follows that NSBB may also reduce 
non- bleeding related mortality.61 246
Despite all this, Lebrec et al194 introduced controversy to the 
beta- blocker story in 2010 when his team reported that patients 
with refractory ascites receiving NSBB had greater all- cause 
mortality during long- term follow- up.247 The window hypoth-
esis has since been proposed, which postulates that refractory 
ascites represents the tipping point in portal hypertension when 
the cardio- inhibitory effects of NSBB compromise organ perfu-
sion.246 Krag and coauthors suggest that the ‘window’ of benefit 
from NSBB opens when grade 2 oesophageal varices develop and 
closes with the development of refractory ascites. Yet, concerns 
have been raised about the methodology of the original observa-
tional study; and many subsequent studies, including five meta- 
analyses and three with propensity risk score matching, have 
shown either similar or superior survival in patients with refrac-
tory ascites receiving NSBB.175 240 247–253 Of relevance is that the 
Lebrec data observed patients receiving a relatively high dose of 
NSBB compared with many of the other cohorts studied, and the 
NSBB type (carvedilol vs propranolol) may be important.247 254
We conclude that, until randomised high- quality data are 
available, the current evidence supports the use of NSBB when 
indicated in patients with refractory ascites (online supplemental 
table 11), unless alternative markers of circulatory failure, 
such as hypotension or reduced glomerular filtration rate, are 
present.175
Recommendation
 ► Refractory ascites should not be viewed as a contraindica-
tion to NSBB. (Quality of evidence: moderate; Recommen-
dation: strong)
 ► Patients with refractory ascites who are taking NSBB should 
be monitored closely, and dose reduction or discontinuation 
may be appropriate in those who develop hypotension or 
acute/progressive renal dysfunction. (Quality of evidence: 
moderate; Recommendation: strong)
AUTOMATED LOW-FLOW ASCITES PUMP (ALFAPUMP)
The ALFApump system consists of a subcutaneously implanted 
battery- powered programmable pump. It is connected to cath-
eters that transfer ascites from the peritoneal cavity to the 
bladder, from which it is eliminated with urine. Initially, two 
multicentre safety and efficacy studies255 256 reported substantial 
reduction of the number and volume of paracenteses in patients 
with advanced cirrhosis and refractory ascites. However, adverse 
effects directly related to the device occurred in up to 39% of 
cases. In a multicentre RCT in patients with refractory ascites, 
the ALFApump significantly reduced the need for paracentesis 
and was associated with significantly improved chronic liver 
disease questionnaire, nutritional parameters such as hand- grip 
strength and body mass index.257 Meta- analysis of the data from 
the RCT and several case series showed that 62% of the patients 
did not require LVP following pump insertion.258 Pooled esti-
mate rates were 30% for acute kidney injury, 27% for bacte-
rial peritonitis and 20% for urinary tract infection. The device 
had no effect on survival. Currently, NICE recommends that the 
ALFApump should be used only with special arrangements for 
clinical governance, consent and audit or research.259
Recommendation
 ► Automated low- flow ascites pump should be considered 
only in special circumstances with robust arrangements of 
clinical governance, audit or research. (Quality of evidence: 
low; Recommendation: weak)
Hepatorenal syndrome
Patients with cirrhosis and ascites can develop a specific form 
of renal dysfunction, which is termed hepatorenal syndrome 
(HRS). Traditionally HRS was thought to be due to the altered 
haemodynamic alterations with hyperdynamic circulation as 
well as overactive endogenous vasoactive system which results 
in renal hypoperfusion.260 It is now recognised that systemic 
inflammation also plays an important role in the pathophysi-
ology of HRS.261 262
The traditional classification of HRS-1 and HRS-2 has 
recently been revised by the International Club of Ascites.263 
HRS-1, which reflects a rapid reduction in renal function, has 
been proposed to be changed to HRS- acute kidney injury (HRS- 
AKI). The new definition of HRS- AKI includes an increase in 
serum creatinine of ≥0.3 mg/dL (27 µmol/L) within 48 hours or 
≥50% from baseline, without necessitating a final cut- off value 
of 1.5 mg/dL (133 µmol/L). This allows treatment to be started 
earlier. HRS-2, which represents renal dysfunction that does not 
progress rapidly, has been proposed to be changed to HRS- NAKI 
(non- AKI).263
The mainstay of treatment of HRS- AKI involves HAS and 
vasoconstrictors, particularly terlipressin. Combination of terlip-
ressin and HAS has been shown in RCTs to significantly improve 
renal function in HRS- AKI and improve short- term mortality 
(online supplemental table 12).264–266 Higher baseline serum 
creatinine is an independent predictor of failure to respond to 
vasoconstrictor treatment.262 267 A full review of HRS is beyond 
the scope of this guideline.
PALLIATIVE CARE
Palliative care is integral to the management of advanced 
non- cancer conditions, such as cardiac, respiratory and renal 
disease, often supported by practice guidelines.268–270 Patients 
with cirrhosis and ascites often report a poor quality of life,271 
this being an independent predictor of 12- month mortality.272 
However, only a minority of patients with advanced cirrhosis 
receive timely palliative care and this has been discussed in 
recent reviews.273 274 A British study indicated that from 2013 
to 2015, of the 45 000 cirrhosis- related deaths, about a third 
required LVP in the last year of their life, overall healthcare costs 
being over £21 000 per person.275
Substantial literature supports the use of palliative tunnelled 
long- term abdominal drains (LTAD) in individuals with refrac-
tory ascites due to malignancy, including NICE medical tech-
nology guidance.276–279 These drains are inserted in hospital and 
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allow drainage of small amounts of ascites 2–3 times a week at 
home. Potential advantages over LVP include symptom- guided 
drainage and avoidance of repeated hospitalisations. A recent 
systematic review on LTAD in cirrhosis showed that the majority 
of patients could be managed in the community.280
Results from a recent feasibility RCT comparing palliative 
LTAD with LVP in refractory ascites due to cirrhosis have just 
been published (REDUCe study).281 In this 3- month study, 
36 patients were randomised, 19 to LVP and 17 to LTAD. All 
patients received prophylactic antibiotics for the study duration. 
Following randomisation, the median number (IQR) of hospital 
ascitic drains for LTAD versus LVP groups were 0 (0, 1) versus 4 
(3, 7), respectively. Only two patients allocated to LTAD required 
hospital admissions specifically for ascites drainage. Self- limiting 
cellulitis/leakage occurred in 41% (7/17) in the LTAD vs 11% 
(2/19) in the LVP group; peritonitis incidence being 6% (1/17) 
vs 11% (2/19), respectively. Median (IQR) fortnightly commu-
nity/hospital/social care ascites- related costs were lower in the 
LTAD group than in the LVP group, £329 (253, 580) versus 
£843 (603, 1060), respectively. Qualitative data (currently only 
published as a summary) indicate that LTAD could transform the 
care pathway.281
The REDUCe study demonstrates feasibility, with preliminary 
evidence of LTAD acceptability, effectiveness and safety and 
reduction in health resource use. Future trials should assess LTAD 
as a palliative intervention for refractory ascites in cirrhosis.
Recommendations
 ► Patients with refractory ascites who are not undergoing eval-
uation for liver transplant should be offered a palliative care 
referral. Besides repeated LVP, alternative palliative inter-
ventions for refractory ascites should also be considered. 
(Quality of evidence: weak; Recommendation: strong)
CONCLUSIONS
The development of ascites is a landmark in the natural history 
of cirrhosis. Therefore, it should be considered an important 
time point at which an individual patient’s suitability for liver 
transplantation which is a definitive treatment of ascites and its 
complications, should be determined. Over the years, there has 
been a substantial improvement in care of patients with cirrhosis, 
including those with ascites. A study involving over 780 000 
hospitalisations of patients with cirrhosis demonstrated an 
improvement in inpatient survival over a decade despite higher 
age and more medically complex disease.282 This was remark-
ably consistent across several cirrhosis complications, suggesting 
improved cirrhosis care beyond general improvements in inpa-
tient care. Future research should focus on areas of need and 
questions where there is no high- quality evidence to guide the 
management of ascites.
RESEARCH RECOMMENDATIONS
 ► Randomised controlled trials (RCTs) with large sample 
size should evaluate the role of antibiotics in the secondary 
prophylaxis for SBP in ascites secondary to cirrhosis.
 ► Large RCTs should assess the role of midodrine in the 
management of ascites.
 ► Cost- effectiveness of long- term administration of HAS to 
patients with decompensated cirrhosis and ascites should be 
evaluated.
 ► Role of nutritional interventions in the management of 
ascites should be evaluated.
 ► Large RCT of long- term carvedilol versus no carvedilol in 
patients with refractory ascites without large oesophageal 
varices should be carried out.
 ► Role of TIPSS in the management of hepatic hydrothorax 
should be compared with other therapeutic interventions.
 ► The cost- effectiveness and the effect of automated low- flow 
ascites pumps on the quality of life of patients with refrac-
tory ascites should be evaluated.
 ► Effectiveness and safety of long- term abdominal drains 
should be assessed in RCTs for the palliative care of patients 
with cirrhosis and refractory ascites.
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